A first-in-human Phase 1/2a update for a B7-H4-targeting antibody-drug conjugate reported partial responses across heavily pretreated ovarian, endometrial, and breast cancer patients, positioning the target for further clinical development. The early results add to growing interest in B7-H4 as an ADC surface antigen. For the market, ADC expansion remains a key theme, but the near-term signal is whether payload and linker approaches are producing tolerable, durable activity in multiple tumor types. The trial’s status as Phase 1/2a means next steps—dose expansion, safety characterization, and response durability—will be critical for translating early efficacy into phase progression.